Burt Ginsburg, MD PA
NPI 1366428245 · Specialist · Houston, TX
Enrolled with Medicare as Practitioner - Ophthalmology · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1366428245
- Entity type
- Individual
- Primary specialty
- SpecialistOther Service Providers
- Credential
- MD PA
- Sex
- Male
- Sole proprietor
- Yes
- License
- H3053 (TX)
Specialties & taxonomies
Other Service Providers
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
20 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
1,653 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Imaging of Retina92134 | 512 | $36 |
| Established Patient Complete Exam of Visual System92014 | 405 | $114 |
| Extended Exam of the Back Part of the Eye With Retinal Drawing92201 | 144 | $22 |
| Photography of the Retina92250 | 112 | $31 |
| Injection of Drug Into Eye67028 | 108 | $117 |
| Exam of Retinal Blood Vessels Using a Special Camera After Injection of a Dye92235 | 95 | $145 |
| Office Or Other Outpatient Visit for the Evaluation and Management of Established Patient That May Not Require Presence of Healthcare Professional |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 12 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Ketorolac Tromethamine | 510 | 128 |
| Diclofenac Sodium | 196 | 52 |
| Bromfenac Sodiumbrand: Prolensa | 192 | 45 |
| Bromfenac Sodium | 115 | 33 |
| Latanoprost | 84 | 22 |
| Lifitegrastbrand: Xiidra | 47 | 15 |
| Brimonidine Tartrate/Timololbrand: Brimonidine Tartrate-Timolol | 27 | — |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$133 across 3 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2005-12-21
- Last updated
- 2012-01-19
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.